KPRX רווח נקי למניה (EPS TTM) Kiora Pharmaceuticals
Geopolitical threats to Kiora Pharmaceuticals (KPRX) are minimal due to the stability of the US regulator. The current EPS TTM level visualizes these risks, where the -2.92 mark characterizes this parameter. Business resilience is based on the development of innovative KIO-301 molecular switches to combat blindness. High scientific authority in treating orphan eye pathologies confirms the company's status as a leading biopharmaceutical innovator.
פילוחי מדדים ואנליטיקה של חברת Kiora Pharmaceuticals (KPRX)
The development of ophthalmological drugs in specialized laboratories at Kiora Pharmaceuticals (KPRX) requires significant capital expenditures. The rolling 12-month EPS metric illustrates the efficiency of these resource allocations per share. This metric aggregates net income over four quarters, excluding the impact of the total shares outstanding. An upward trend confirms the monetization of research, while stagnation signals a high-cost period. This indicator determines the real return on investor capital.
